title: [The use of recombinant interleukin-2 in children with encephalitis].
abstract: OBJECTIVE
  To study the efficacy of the domestic recombinant interleukin-2 (IL-2) in the complex treatment of encephalitis.
  
  
  METHODS
  Forty patients, aged from 6 months to 17 years, were treated with the drug. A comparison group involved 35 patients who did not receive the drug.
  
  
  RESULTS
  Recombinant IL-2 reduced (p<0.05) the aggravation of symptoms to 5.4±1.3 days, neurological deficit (1.6±0.2 EDSS scores at discharge from the hospital), frequency of exacerbations (from 22.9 to 5%) and frequency of cases with the development of multiple sclerosis during 3 years (from 17.1 to 2.5%). Parameters of the drug efficacy were correlated with positive changes in immunological parameters after 3-4 days of treatment. The study of multimodal evoked potentials demonstrated the positive effect of the drug on the central afferent conduction times. The follow-up MRI examination showed the decrease in the frequency of focal changes.
  
  
  CONCLUSIONS
  Recombinant IL-2 is recommended for treatment of children with encephalitis.
authors.forename: N V
authors.initials: NV
authors.lastname: Skripchenko
authors.forename: G P
authors.initials: GP
authors.lastname: Ivanova
authors.forename: G F
authors.initials: GF
authors.lastname: Zheleznikova
authors.forename: V N
authors.initials: VN
authors.lastname: Komantsev
authors.forename: A V
authors.initials: AV
authors.lastname: Surovtseva
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004660:Encephalitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007223:Infant; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000209:etiology / Q000517:prevention & control; D010351:Patient Discharge; D016896:Treatment Outcome
chemical_list: D007376:Interleukin-2